RVTY:NYE-Revvity Inc. (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 102.83

Change

-0.34 (-0.33)%

Market Cap

USD 12.54B

Volume

0.49M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-08 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
DHR Danaher Corporation

N/A

USD 178.95B
A Agilent Technologies Inc

N/A

USD 39.27B
IQV IQVIA Holdings Inc

N/A

USD 37.96B
LH Laboratory Corporation of Amer..

N/A

USD 19.60B
DGX Quest Diagnostics Incorporated

N/A

USD 17.54B
QGEN Qiagen NV

N/A

USD 9.57B
CRL Charles River Laboratories

N/A

USD 9.42B
VNRX Volitionrx Ltd

N/A

USD 0.06B
ENZ Enzo Biochem Inc

N/A

USD 0.06B
MTD Mettler-Toledo International I..

N/A

N/A

ETFs Containing RVTY

FLWR:SW 14.15 % 0.00 %

N/A

N/A
XMLH:XETRA L&G Healthcare Breakthrou.. 1.78 % 0.00 %

N/A

USD 0.07B
XMLH:F Legal & General Ucits Etf.. 1.78 % 0.00 %

N/A

USD 0.07B
DOCT:SW L&G Healthcare Breakthrou.. 1.78 % 0.00 %

N/A

USD 0.06B
HTEC Robo Global® Healthcare .. 1.73 % 0.00 %

N/A

USD 0.06B
DOCG:LSE L&G Healthcare Breakthrou.. 1.70 % 0.00 %

N/A

USD 0.07B
DOCT:LSE L&G Healthcare Breakthrou.. 1.70 % 0.00 %

N/A

USD 0.07B
ZUH:CA BMO Equal Weight US Healt.. 1.48 % 0.39 %

N/A

CAD 0.26B
ZHU:CA BMO Equal Weight US Healt.. 1.48 % 0.00 %

N/A

CAD 0.01B
EWSP:SW iShares S&P 500 Equal Wei.. 0.23 % 0.00 %

N/A

USD 2.57B
BLUM:XETRA 0.00 % 0.00 %

N/A

N/A
BLUM:F 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -5.93% 21% F 20% F
Dividend Return 0.13% 43% F 5% F
Total Return -5.80% 21% F 18% F
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 12.54B 31% F 86% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector